Track topics on Twitter Track topics that are important to you
Alchemia was established in Australia in 1995 by three scientists, Professor Peter Andrews, Dr Tracie Ramsdale and Professor Istvan Toth, who joined forces to take on the formidable challenge of unlocking the therapeutic potential of carbohydrates - one of the last remaining groups of biological macromolecules with significant untapped potential. In early 1998 it established its research laboratories in Brisbane, Australia. The Company has raised $26 million from a number of specialised biotechnology investors between 1998 and 2003, and has also received strong support from the Australian Federal Government through receipt of $7 million to date, from the Federal Government's R&D START Program. In December 2000, Alchemia entered into a strategic manufacturing alliance with The Dow Chemical Company, the largest global chemical manufacturer, to jointly develop commercial processes for the manufacture of carbohydrates of high therapeutic value. In October 2003, Alchemia entered into a partnership with American Pharmaceutical Partners, a US specialty pharmaceutical company, to bring to market the first product of the Alchemia-Dow alliance, a generic version of the first branded synthetic heparin product, Arixtra®. The anticipated market launch of this product is 2008. Alchemia has developed a proprietary drug discovery platform, VAST™, from which it is investigating several key anti-angiogenic compounds with the aim of developing therapeutics to meet significant unmet medical need. Alchemia's first drug candidate, an anti-cancer agent, is due to commence human clinical trials at the start of 2006. Alchemia (ASX:ACL) listed on the Australian Stock Exchange, in December 2003, raising $21 million and completed a level 1 NASDAQ registration in November 2004.
PO Box 6947
United States of America
In this exclusive interview, Fintan Walton talks to Pete Smith, CEO of Alchemia, about the origins of the company in carbohydrate chemistry, and how these origins led to a unique position in the manuf...
Alchemia Ltd ACL Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData t...
SummaryAlchemia Ltd Alchemia is a clinical stage biopharmaceutical company which focuses on the research and development drugs for the treatment of cancer and other therapeutic areas, such as cardiova...
Alchemia was established in Australia in 1995 by three scientists, Professor Peter Andrews, Dr Tracie Ramsdale and Professor Istvan Toth, who joined forces to take on the formidable challenge of unloc...
Alchemia has become internationally recognised for its unique platform technology for the production of complex sugar-based molecules called oligosaccharides.Oligosaccharides play pivotal roles in man...
Implicit Bioscience Pty Ltd is an immunology-focused drug development company headquartered in Brisbane, Australia; Implicit's US subsidiary, Implicit Bioscience, Inc., is located on the San Francisco...
The Companyâs lead program is fondaparinux (a generic version of GlaxoSmithKlineâs ArixtraÂ®, a synthetic anticoagulant mainly used for the prevention of deep vein thr...
We have published hundreds of Alchemia news stories on BioPortfolio along with dozens of Alchemia Clinical Trials and PubMed Articles about Alchemia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alchemia Companies in our database. You can also find out about relevant Alchemia Drugs and Medications on this site too.
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...